Zhitong Finance App News, Weilizhibo-B (09887.HK) announced that the full text of the Phase II clinical study summary for first-line treatment of non-small cell lung cancer (NSCLC) with the drug Velisin™ (opatisumimab, PD L1/4-1BB bispecific antibody), developed independently by the company, has been officially released on the official website of the World Lung Cancer Conference (WCLC). Based on data analysis as of March 6, 2026, Verisin™ combined chemotherapy showed an encouraging objective remission rate (ORR) in the overall population, while strong tumor shrinkage effects were observed in both squamous cell carcinoma and non-squamous cell carcinoma subgroups. The data disclosed in the abstract is based on a follow-up of only 3.6 months, and the latest data with a follow-up period of more than seven months will be announced during the WCLC oral presentation on September 14, 2026.

Zhitong Finance App News, Weilizhibo-B (09887.HK) announced that the full text of the Phase II clinical study summary for first-line treatment of non-small cell lung cancer (NSCLC) with the drug Velisin™ (opatisumimab, PD L1/4-1BB bispecific antibody), developed independently by the company, has been officially released on the official website of the World Lung Cancer Conference (WCLC). Based on data analysis as of March 6, 2026, Verisin™ combined chemotherapy showed an encouraging objective remission rate (ORR) in the overall population, while strong tumor shrinkage effects were observed in both squamous cell carcinoma and non-squamous cell carcinoma subgroups. The data disclosed in the abstract is based on a follow-up of only 3.6 months, and the latest data with a follow-up period of more than seven months will be announced during the WCLC oral presentation on September 14, 2026.